

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: HuaZhu Ke, et al.

Examiner: To Be Assigned

APPLICATION NO.: To Be Assigned

FILING DATE: Herewith

:Group Art Unit: To Be Assigned

TITLE: Combination Therapy for Osteoporosis

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

Copending application U.S. Serial No. 09/178,949, filed October 26, 1998, has been allowed with respect to original claims 1-7 and 11. Both this application and the copending application claim priority to PCT/IB97/01383, filed November 4, 1997.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date:

12/13/00

Robert T. Ronau
Robert T. Ronau

Attorney for Applicant(s)

Reg. No. 36,257

Pfizer Inc.
Patent Department, Box 519
Eastern Point Road
Groton, CT 06340
(860) 441-5910

EXPRESS MAIL NO. EL 63394912565

4/97, M2, (1/2)

